Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.K. manufacturing subsidiary Eisai Manufacturing Ltd. (EML) situated within the company's European Knowledge Centre (EKC), has received a license (marketing authorization type II variation: addition of manufacturing site) from the European regulatory authorities for solid dose manufacturing of the antiepileptic agent Fycompa(R) (perampanel), a first-in-class AMPA receptor antagonist discovered and developed in-house, at its Hatfield production plant. Eisai celebrated this occasion with a ceremony to mark the official opening of a new Fycompa manufacturing line.
